Literature DB >> 2255590

Dissolution profiles of mesalazine formulations in vitro.

L M Stolk1, R Rietbroek, E H Wiltink, J J Tukker.   

Abstract

In vitro dissolution profiles of three controlled-release mesalazine formulations were determined at pH 1.0, 6.0 and 7.5. A closed-column type dissolution apparatus was used. A reproducible gradual dissolution profile was seen for Pentasa at all pH values. Dissolution starts immediately and is complete after 20 h. Dissolution profiles at pH 1 and pH 7.5 are much alike and dissolution is faster than at pH 6. The behaviour of Asacol at different pH values corresponds with the expectations: no release at pH 6 and pH 1, fast release at pH 7.5. Dissolution starts after 1 h and is complete after 3 h. Mesalazine release from Salofalk tablets at pH 7.5 and pH 6.0 starts after 2 and 3 h, respectively, and is complete after 5 and 10 h. However, after a long lag-time (10 h) mesalazine is also released from Salofalk tablets at pH 1 and dissolution is complete after 23 h.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2255590     DOI: 10.1007/bf01980047

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  3 in total

1.  Measurement of gastrointestinal pH profiles in normal ambulant human subjects.

Authors:  D F Evans; G Pye; R Bramley; A G Clark; T J Dyson; J D Hardcastle
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

2.  Simple and sensitive high-performance liquid chromatographic assay for 5-aminosalicylic acid and acetyl-5-aminosalicylic acid in serum.

Authors:  E J Lee; S B Ang
Journal:  J Chromatogr       Date:  1987-01-23

Review 3.  Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.

Authors:  G Järnerot
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

  3 in total
  4 in total

1.  Small intestinal transit time and intraluminal pH in ileocecal resected patients with Crohn's disease.

Authors:  J Fallingborg; P Pedersen; B A Jacobsen
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 2.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 3.  New developments in the pharmacotherapy of inflammatory bowel disease.

Authors:  J W Harting
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

4.  Artificial Neural Network (ANN) Approach to Predict an Optimized pH-Dependent Mesalamine Matrix Tablet.

Authors:  Asad Majeed Khan; Muhammad Hanif; Nadeem Irfan Bukhari; Rahat Shamim; Fatima Rasool; Sumaira Rasul; Sana Shafique
Journal:  Drug Des Devel Ther       Date:  2020-06-22       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.